Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Prostate Cancer
Intervention: etoposide (Drug); mitoxantrone hydrochloride (Drug); prednisone (Drug); vinorelbine ditartrate (Drug)
Phase: Phase 2
Sponsored by: Groupe D'Etude des Tumeurs Uro-Genitales
Official(s) and/or principal investigator(s):
Florence Joly, MD, PhD, Study Chair, Affiliation: Centre Francois Baclesse
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone, etoposide, and vinorelbine,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. It is not yet known which drug is more effective in killing
PURPOSE: This randomized phase II trial is studying how well mitoxantrone works compared to
etoposide or vinorelbine works as second-line therapy in treating patients with metastatic
prostate cancer that did not respond to hormone therapy.
Official title: Phase 2 Randomized Study Evaluating 3 Chemotherapy Regimens as Second-line Treatment in Patients With Hormone-refractory Metastatic Prostate Cancer
Study design: Allocation: Randomized, Primary Purpose: Treatment
Primary outcome: Palliative response rate
Duration of palliative response
Tumor response as assessed by RECIST criteria
Time to progression
Quality of life as assessed by QLQ-PR25
Impact on autonomy in patients > 70 years of age
- Determine the palliative response rate in patients with hormone-resistant prostate
cancer treated with mitoxantrone hydrochloride vs etoposide vs vinorelbine ditartrate
as second-line therapy.
- Determine the duration of palliative response in patients treated with these regimens.
- Determine the biological response (PSA > 50%) in these patients.
- Determine the time to progression (biological and clinical) in these patients.
- Determine the overall survival of these patients.
- Determine the quality of life and the impact on autonomy of patients over 70 years of
- Determine the toxicity of these regimens in these patients.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive mitoxantrone hydrochloride IV over 5 minutes once a week for 3
- Arm II: Patients receive oral etoposide twice daily on days 1-14.
- Arm III: Patients receive oral vinorelbine ditartrate once daily on days 1 and 8 and
oral prednisone once daily on days 1-21.
Treatment in all three arms repeats every 3 weeks for up to 9 courses in the absence of
disease progression or unacceptable toxicity.
Minimum age: 18 Years.
Maximum age: N/A.
- Histologically confirmed adenocarcinoma of the prostate
- Metastatic progressive disease meeting the following criteria:
- Increase in measurable lesions > 25%
- Increase in bone lesions > 25%
- Biological progression rate of PSA > 4 ng/mL
- Received docetaxel as first-line chemotherapy
- Received at least 1 prior regimen of hormone therapy
- Pain > 2 on Visual Analog Scale or continuing level 2 analgesics
- No symptomatic or evolutionary CNS disease
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Creatinine ≤ 1. 5 times normal
- Alkaline phosphatase ≤ 2 times normal (unless bone metastases are present)
- Transaminases ≤ 1. 5 times normal
- Bilirubin ≤ 1. 5 times normal
- No prior malignancy except basal cell skin cancer
- No peripheral neuropathy or severe neuropathy ≥ grade 2
- No other severe lung, hepatic, renal, or digestive disease that would be complicated
- LVEF > 50%
- No history of peptic ulcer, unstable diabetes, or other contraindication to using
- No severe infection requiring antibiotics
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 8 weeks since prior metabolic radiotherapy
- More than 4 weeks since prior external radiotherapy
- At least 1 month since prior docetaxel-based chemotherapy
- At least 1 month since prior antiandrogen therapy in the case of complete hormonal
- No participation in another clinical trial within the past 30 days
Locations and Contacts
Centre Regional Francois Baclesse, Caen 14076, France; Recruiting
Florence Joly, MD, PhD, Phone: 33-02-31-45-50-17, Email: firstname.lastname@example.org
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: September 2006
Last updated: December 13, 2009